Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | F2 | P00734 | 13/20 | 0.46 |
| ▸ | F10 | P00742 | 3/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | F12 | P00748 | 1/20 | 0.43 |
| ▸ | F7 | P08709 | 1/20 | 0.43 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7374631 | 0.84 | F2 (0.51) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL7370693 | 0.84 | ALDH1A1 (0.49) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL7406947 | 0.84 | ALDH1A1 (0.46) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL7381541 | 0.83 | F2 (0.49) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL6925082 | 0.83 | ALDH1A1 (0.64) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL7378516 | 0.82 | ALDH1A1 (0.47) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL7380524 | 0.82 | F2 (0.53) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL7377365 | 0.82 | F2 (0.49) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL7452387 | 0.82 | F2 (0.52) | ALDH1A1F2F10PRSS1PRSS2 | |
| SCHEMBL7376773 | 0.81 | ALDH1A1 (0.46) | ALDH1A1F2F10PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6515011-B2 | Anticoagulants | MERCK & CO., INC. | 2003-02-04 | — | — | US | disclosed |
| US-20020119992-A1 | Thrombin inhibitors | MERCK & CO., INC. | 2002-08-29 | — | — | US | disclosed |
| WO-2002050056-A1 | BENZYLAMINE DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | MERCK & CO., INC. (US) | 2002-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119992-A1 | Thrombin inhibitors | SERPINC1, F2, TFPI | ALDH1A1 4773/4885F2 2/4885F10 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.